Toray Industries, Inc clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.

1. Notable

   TRK-950 When Used in Combination With Ramucirumab and Paclitaxel…TRK-950 When Used in Combination With Ramucirumab and Paclitaxel · Gastric Cancer

   Primary and study completion pushed from Jun 30, 2026 to Oct 31, 2027

   Toray Industries, Inc·Phase 2· NCT06038578· Registry history of NCT06038578 on ClinicalTrials.gov (opens the registry)

   Updated Oct 8, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.